Oncology History Main Article

Daiichi Sankyo Cancer Enterprise Milestones

Oncology History

  • 2017
    April 2017

    Daiichi Sankyo announced an initial 15 billion yen investment to optimize and enhance its manufacturing capabilities to support its growing antibody drug conjugate (ADC) pipeline

  • January 2017

    Phase 1 study initiated in Japan evaluating safety and efficacy of U3-1402 in HER3-positive metastatic or unresectable breast cancer

  • 2016
    December 2016

    Daiichi Sankyo enters into strategic partnership with DarwinHealth to deploy a quantitative systems biology discovery platform to prioritize Daiichi Sankyo Cancer Enterprise compounds for development

  • November 2016

    DS-8201 granted Fast Track designation by the FDA for the treatment of HER2-positive unresectable and/or metastatic breast cancer in patients who have progressed after prior treatment with HER2-targeted therapies including ado-trastuzumab emtansine (T-DM1).

  • 2016
    October 2016

    Daiichi Sankyo enters into cross-licensing and collaboration agreement with ZymeWorks to develop a bi-specific antibody therapeutic

  • October 2016

    Daiichi Sankyo enters into a preclinical lung cancer research collaboration with Dana-Farber Cancer Institute

  • 2016
    October 2016

    Patritumab selected for inclusion in I-SPY2 TRIAL in breast cancer

  • October 2016

    Daiichi Sankyo enters into strategic collaboration with AgonOx, Inc. to develop undisclosed immune-oncology target

  • 2016
    October 2016

    Phase 3 QuANTUM-First study initiated examining safety and efficacy of quizartinib in newly-diagnosed FLT3-ITD-mutated AML

  • April 2016

    Antoine Yver, MD, MSc, appointed to Global Head, Oncology Research and Development, responsible for leading global research and development across the oncology therapeutic area

  • 2016
    March 2016

    Daiichi Sankyo announced 2025 Vision to become a "Global Pharma Innovator with a Competitive Advantage in Oncology"

  • November 2015

    Cobimetinib plus Zelboraf received FDA approval. Began co-promotion in the US with Genentech

  • 2015
    October 2015

    Pexidartinib granted Breakthrough Therapy Designation by the FDA for the treatment of tenosynovial giant cell tumor (TGCT)

  • August 2015

    Generic name for PLX3397, pexidartinib, recommended by the International Nonproprietary Names (INN) for Pharmaceutical Substances

  • 2015
    July 2015

    PLX3397 phase 1 extension data published in The New England Journal of Medicine

  • November 2014

    Acquired Ambit Biosciences to expand oncology pipeline

  • 2014
    February 2014

    PLX3397 granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA)

  • April 2012

    Launched Ranmark® (denosumbab) in Japan for treatment of bone complications stemming from multiple myeloma and bone metastases from solid tumors.

  • 2011
    August 2011

    Received FDA approval of Zelboraf® (vemurafenib). Co-promotion with Genentech began.

  • April 2011

    Acquired Plexxikon Inc. for oncology pipeline and drug development

  • 2009
    March 2009

    Quizartinib granted Orphan Drug Designation by the FDA (received by Ambit Biosciences prior to becoming part of Daiichi Sankyo)

  • May 2008

    Acquired U3 Pharma, a company with a pipeline of targeted antibody therapeutics for cancer

  • 1995

    Received approval of irinotecan in Japan, the first chemotherapy to demonstrate survival benefits in colorectal cancer

  • 1985

    Launched the first natural-type interferon beta preparation for brain tumor and skin cancer in Japan

  • 1977

    Launched Krestin® (Polysaccharide-K) in Japan to treat digestive, lung and breast cancer

Oncology more stories content

More Stories

Daiichi Sankyo Cancer Enterprise

The vision of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer.

read more ...